These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 10184610

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE, Bona RD, Rickles FR.
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [Abstract] [Full Text] [Related]

  • 23. AIDS and immunologic abnormalities in European and American hemophiliacs.
    Green D.
    Scand J Haematol Suppl; 1984 Mar; 40():367-9. PubMed ID: 6433463
    [No Abstract] [Full Text] [Related]

  • 24. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

  • 25. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
    Werwitzke S, Tiede A, Stoll M, von Depka M.
    J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985
    [No Abstract] [Full Text] [Related]

  • 26. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.
    Berntorp E, Iorio A.
    Blood; 2015 Jun 11; 125(24):3816-7. PubMed ID: 26069334
    [No Abstract] [Full Text] [Related]

  • 27. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM, Kaijen PH, Mauser-Bunschoten EP, Fischer K, van den Berg HM, Voorberg J.
    Haemophilia; 2010 Nov 11; 16(6):892-901. PubMed ID: 20491952
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Suggestions for the management of factor VIII inhibitors.
    Rubinger M, Rivard GE, Teitel J, Walker H, Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2000 Jul 11; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII.
    Gordon EM, Mungo R, Goldsmith JC.
    Am J Pediatr Hematol Oncol; 1993 Feb 11; 15(1):107-10. PubMed ID: 8447550
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A, Roisenberg I.
    Thromb Haemost; 1999 Mar 11; 81(3):475-6. PubMed ID: 10102489
    [No Abstract] [Full Text] [Related]

  • 36. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates.
    Soria AG, Bouzas MB, Anselmo A, Ruibal-Ares BH.
    Haematologica; 1991 Mar 11; 76(1):33-7. PubMed ID: 1829058
    [Abstract] [Full Text] [Related]

  • 37. Porcine factor VIII: past, present and future.
    Hay CR.
    Haematologica; 2000 Oct 11; 85(10 Suppl):21-4; discussion 24-5. PubMed ID: 11187865
    [Abstract] [Full Text] [Related]

  • 38. Management of factor VIII inhibitors.
    Dimichele DM.
    Int J Hematol; 2006 Feb 11; 83(2):119-25. PubMed ID: 16513529
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.